The current break-fix healthcare models do not align with the chronicity of clinical obesity and must be augmented with accessible, sustainable, and effective post-treatment models of care to maintain the positive weight outcomes associated with GLP-1/GIP RA class medications. This evidence concerns the gene GLP1R and Obesity.